Combivir

DRUG5 trials

Sponsors

GlaxoSmithKline, ViiV Healthcare, St. Luke's-Roosevelt Hospital Center

Conditions

HIVHIV InfectionHIV InfectionsInfection, Human Immunodeficiency Virus I

Phase 1

A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™

CompletedNCT01597648

GlaxoSmithKlineInfection, Human Immunodeficiency Virus I

Start: 2011-11-30End: 2012-01-31Updated: 2012-05-21

Phase 2

GW873140 In Combination With Combivir In HIV Infected Subjects

TerminatedNCT00104429

ViiV HealthcareHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2005-01-31End: 2006-01-31Target: 125Updated: 2017-05-30

Phase 3

Study to Explore Safety And Tolerability of Fosamprenavir With or Without Ritonavir in Combination With TRIZIVIR or COMBIVIR

CompletedNCT00043888

GlaxoSmithKlineHIV Infections

Start: 2002-01-31End: 2003-05-31Target: 60Updated: 2013-02-12

Phase 4

A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV

CompletedNCT00082394

GlaxoSmithKlineHIV Infection, Infection, Human Immunodeficiency Virus I

Start: 2004-04-26End: 2006-03-01Updated: 2017-05-24

Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects

CompletedNCT00960622

St. Luke's-Roosevelt Hospital CenterHIV

Start: 2006-08-31End: 2009-07-31Updated: 2013-03-04

Related Papers

A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study).

2009-04-0915 citations